Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer.

被引：0
|
作者：
Gilbert, Lucy
Oaknin, Ana
Matulonis, Ursula A.
Mantia-Smaldone, Gina
Lim, Peter C.
Castro, Cesar Martin
Provencher, Diane M.
Memarzadeh, Sanaz
Wang, Jiuzhou
Esteves, Brooke
Zweidler-McKay, Patrick A.
Moore, Kathleen N.
O'Malley, David M.
机构：
[1] McGill Univ, Royal Victoria Hosp, Hlth Ctr, Montreal, PQ, Canada
[2] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[5] Renown Reg Med Ctr, Ctr Hope, Reno, NE USA
[6] Harvard Med Sch, Massachusetts Gen Hosp, Reading, MA USA
[7] Univ Montreal, Montreal, PQ, Canada
[8] Univ Calif Los Angeles, Los Angeles, CA USA
[9] ImmunoGen Inc, Waltham, MA USA
[10] Kadmon Rsrch Inst, Wilmington, MA USA
[11] ImmunoGen, Waltham, MA USA
[12] Univ Oklahoma, Med Ctr, Oklahoma City, OK USA
[13] Ohio State Univ, Coll Med, Columbus, OH 43210 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6004
引用
收藏
页数：2
相关论文
共 50 条
  • [31] The efficacy and toxicity of mirvetuximab soravtansine, a novel antibody-drug conjugate, in the treatment of advanced or recurrent ovarian cancer: a meta-analysis
    Xu, Ke
    Wang, Tianlei
    Pan, Shenbin
    He, Jie
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2023, 16 (11) : 1141 - 1152
  • [32] Mirvetuximab soravtansine (MIRV) in recurrent platinum-sensitive ovarian cancer (PSOC) with high folate receptor-alpha (FRα) expression: Results from the PICCOLO trial
    Secord, A. A.
    Corr, B. R.
    Lewin, S.
    Diver, E.
    Ayuk, S-M.
    Wang, Y.
    Murphy, C.
    Salutari, V.
    Garcia, A. Barquin
    Montosa, F. Galvez
    Ray-Coquard, I. L.
    Mathews, C.
    Konecny, G. E.
    Oaknin, A.
    Perez, M. J. Rubio
    Bonaventura, A.
    Pignata, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S549 - S550
  • [33] Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study
    Matulonis, Ursula A.
    Lorusso, Domenica
    Oaknin, Ana
    Pignata, Sandro
    Dean, Andrew
    Denys, Hannelore
    Colombo, Nicoletta
    Van Gorp, Toon
    Konner, Jason A.
    Marin, Margarita Romeo
    Harter, Philipp
    Murphy, Conleth G.
    Wang, Jiuzhou
    Noble, Elizabeth
    Esteves, Brooke
    Method, Michael
    Coleman, Robert L.
    OBSTETRICAL & GYNECOLOGICAL SURVEY, 2023, 78 (06) : 343 - 344
  • [34] Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study
    Matulonis, Ursula A. A.
    Lorusso, Domenica
    Oaknin, Ana
    Pignata, Sandro
    Dean, Andrew
    Denys, Hannelore
    Colombo, Nicoletta
    Van Gorp, Toon
    Konner, Jason A. A.
    Marin, Margarita Romeo
    Harter, Philipp
    Murphy, Conleth G. G.
    Wang, Jiuzhou
    Noble, Elizabeth
    Esteves, Brooke
    Method, Michael
    Coleman, Robert L. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (13) : 2436 - +
  • [35] Efficacy and Safety of Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha Expression: Results from the SORAYA Study
    Matulonis, Ursula
    Lorusso, Domenica
    Oaknin, Ana
    Pignata, Sandro
    Denys, Hannelore
    Colombo, Nicoletta
    Van Gorp, Toon
    Konner, Jason
    Romeo Marin, Margarita
    Harter, Philipp
    Murphy, Conleth
    Wang, Jiuzhou
    Noble, Elizabeth
    Esteves, Brooke
    Method, Michael
    Coleman, Robert
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S50 - S50
  • [36] Folate receptor alpha for cancer therapy: an antibody and antibody-drug conjugate target coming of age
    Liu, Yi
    Chen, Xinyi
    Evan, Theodore
    Esapa, Benjamina
    Chenoweth, Alicia
    Cheung, Anthony
    Karagiannis, Sophia N.
    MABS, 2025, 17 (01)
  • [37] MIRVETUXIMAB SORAVTANSINE AND CARBOPLATIN FOR TREATMENT OF PATIENTS WITH RECURRENT FOLATE RECEPTOR ALPHAPOSITIVE PLATINUM-SENSITIVE OVARIAN CANCER: A FINAL ANALYSIS
    Moore, Kathleen
    O'Malley, David
    Vergote, Ignace
    Martin, Lainie
    Gonzalez-Martin, Antonio
    Wang, Jiuzhou
    Method, Michael
    Birrer, Michael
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A33 - A34
  • [38] Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: Evaluation of sequence of therapy on anti-tumor activity in the SORAYA study
    Coleman, Robert
    Oaknin, Ana
    Pignata, Sandro
    Denys, Hannelore
    Colombo, Nicoletta
    Van Gorp, Toon
    Konner, Jason
    Marin, Margarita Romeo
    Harter, Philipp
    Murphy, Conleth
    Esteves, Brooke
    Method, Michael
    Lorusso, Domenica
    Matulonis, Ursula
    GYNECOLOGIC ONCOLOGY, 2023, 176 : S3 - S3
  • [39] Bystander activity and in vivo efficacy of a folate receptor α (FRα)-targeting antibody-drug conjugate with a novel peptide linker
    Qiu, Qifeng
    Wu, Rui
    Lanieri, Leanne
    Maloney, Erin
    Skaletskaya, Anna
    Jin, Shan
    Wang, Lintao
    Ab, Olga
    Ponte, Joe
    Setiady, Yulius
    Widdison, Wayne
    Keating, Thomas
    Chari, Ravi
    Gregory, Richard
    Hong, Erica
    CANCER RESEARCH, 2017, 77
  • [40] CLINICAL BENEFIT OF MIRVETUXIMAB SORAVTANSINE IN OVARIAN CANCER PATIENTS WITH HIGH FOLATE RECEPTOR ALPHA EXPRESSION: RESULTS FROM THE SORAYA STUDY
    Coleman, Robert L.
    Matulonis, Ursula
    Lorusso, Domenica
    Oaknin, Ana
    Pignata, Sandro
    Denys, Hannelore
    Colombo, Nicoletta
    Van Gorp, Toon
    Konner, Jason
    Romeo Marin, Margarita
    Harter, Philipp
    Murphy, Conleth
    Wang, Jiuzhou
    Noble, Elizabeth
    Esteves, Brooke
    Method, Michael
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A18 - A18
12345